NASDAQ · ORKA
Oruka Therapeutics, Inc.
$95.48-$1.17 (-1.22%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.35% below the high.
Loading market information…
NASDAQ · CERC · USD
Stock price, earnings
Quote as of Aug 26, 2021, 04:00 AM UTC. Cached market data; not a live quote.
Price history is currently unavailable.
Cerecor Inc.’s quoted price sits in the lower half of its reported 52-week range, 1.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cerecor Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cerecor Inc. operates as a biopharmaceutical firm dedicated to the discovery and marketing of therapeutic solutions, primarily addressing rare pediatric and orphan diseases. The company maintains an active pipeline, including: Inherited Metabolic Disorders: Advancing CERC-801 and CERC-802, both of which have successfully completed Phase I clinical trials, alongside CERC-803. Autoimmune Inflammatory Conditions: Developing CERC-007, an anti-IL-18 monoclonal antibody, designed to combat ailments such as adult-onset Still's disease and multiple myeloma. Complex Lymphatic Malformations: Progressing CERC-006, a dual mTOR inhibitor. Pediatric-onset Crohn's Disease: Working on CERC-002, an anti-LIGHT monoclonal antibody. Mitochondrial Disorders: Investigating CERC-913, a protide nucleotide. Rare Auto-inflammatory Diseases: Developing CERC-005, a monoclonal antibody. Symptomatic Orthostatic Hypotension: Pursuing CERC-301. Parkinson's Disease: Researching CERC-406. Beyond its research and development efforts, Cerecor also markets Millipred, an oral prednisolone formulation used to manage various inflammatory ailments. These include conditions affecting the joints (arthritis), blood, immune system, skin, eyes, respiratory system, as well as certain cancers and severe allergies. Established in 2011, when it rebranded from Ceregen Corporation to Cerecor Inc., the company's headquarters are situated in Rockville, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 9, 2019 |
|---|
| May 9, 2019 |
| -$0.13+18.75% vs estimate |
| $0.00 |
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$95.48-$1.17 (-1.22%)
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 17.35% below the high.
$3.61-$0.04 (-1.23%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.01% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
$5.41-$0.20 (-3.57%)
Qilian International Holding Group Limited’s quoted price sits in the upper half of its reported 52-week range, 19.13% below the high.
$4.34$0.00 (0.0%)
Lumos Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.15% below the high.
$1.10$0.00 (0.0%)
Satsuma Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.39% below the high.
$1.91-$0.04 (-1.8%)
Grace Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.22% below the high.
